- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Tatva Chintan Pharma Chem reported Q1 FY26 revenue up 11% YoY to ₹116.9 Cr and EBITDA up 37% to ₹17.3 Cr, with margins at 14.8%. PAT grew 27% to ₹6.6 Cr. Management notes positive business sentiment, expecting H2 improvement. SDA demand is reviving, with Euro 7 opportunities emerging. New agro/pharma intermediates and electrolyte salts are set for commercialization in H2, supported by strong order visibility. Semiconductor development shows promising pilot results. The company targets over 25% revenue growth and 20% margins for FY26, signaling confidence in sustained performance.